Sugi Predict

Sugi Predict / Compounds / SCHEMBL13618306

SCHEMBL13618306

SCHEMBL13618306

CO[C@H]1[C@@H](O)[C@H](n2ccc(=O)[nH]c2=O)O[C@@H]1[C@@H](O[C@H]1OC(C(=O)N[C@H]2CCC[C@@H](C)NC2=O)=C[C@H](O)[C@@H]1O)C(N)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ DPAGT1 Q9H3H5 5/20 0.76
▸ P2RY6 Q15077 1/20 0.35
▸ P2RY2 P41231 1/20 0.34
▸ P2RY4 P51582 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13625829 0.90 DPAGT1 (0.62) DPAGT1P2RY6P2RY2P2RY4
Capuramycin SCHEMBL14598937 0.90 DPAGT1 (0.92) DPAGT1P2RY6P2RY2P2RY4
Capuramycin SCHEMBL15472874 0.90 DPAGT1 (0.92) DPAGT1P2RY6P2RY2P2RY4
Capuramycin SCHEMBL16525934 0.90 DPAGT1 (0.92) DPAGT1P2RY6P2RY2P2RY4
SCHEMBL13618307 0.89 DPAGT1 (0.61) DPAGT1P2RY6P2RY2P2RY4
SCHEMBL20032916 0.89 DPAGT1 (0.69) DPAGT1P2RY6P2RY2P2RY4
SCHEMBL13618308 0.88 DPAGT1 (0.69) DPAGT1
SCHEMBL14598959 0.88 DPAGT1 (0.75) DPAGT1
SCHEMBL14598957 0.88 DPAGT1 (0.75) DPAGT1
SCHEMBL14583641 0.87 DPAGT1 (0.65) DPAGT1P2RY6P2RY2P2RY4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009136965-A1 COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES SEQUELLA, INC. (US) 2009-11-12 — — WO disclosed
US-20090281054-A1 COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES SEQUELLA, INC. 2009-11-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281054-A1 COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES TTPA, PHOSPHO1, CAPG DPAGT1 309/4885P2RY6 3295/4885P2RY2 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.